Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 354 participants.
Also called NCT01592240
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 354 participants
- Sponsor
- Registry
-
NCT01592240 -
2012-001226-10
-
- Other papers using this trial's data
- Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01592240. Randomized; triple masking; primary purpose treatment. Start 2012-07 (actual); primary completion 2013-04 (actual). Results posted on 2017-12-05.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- PBO
- Intervention (Drug)
- 200mg PF-04950615 (RN316)
- Intervention (Drug)
- 300mg PF-04950615 (RN316)
- Intervention (Drug)
- PBO
- Intervention (Drug)
- PF-04950615
- Intervention (Drug)
- PF-04950615
- Intervention (Drug)
- PF-04950615
- Lead sponsor
- Pfizer
Record details
- Record id
cardio:ct-nct01592240- Content hash
a5a8e137a60897f8d7b3d15825aae804ffd30fdb1f47f1366abfad9b847bf3f0